Stifel Financial Corp Lowers Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Stifel Financial Corp decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,003,198 shares of the medical equipment provider's stock after selling 5,083 shares during the period. Stifel Financial Corp owned approximately 0.14% of Boston Scientific worth $178,926,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Parnassus Investments LLC lifted its holdings in shares of Boston Scientific by 0.7% during the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after purchasing an additional 97 shares in the last quarter. Evergreen Capital Management LLC boosted its holdings in Boston Scientific by 1.7% in the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after purchasing an additional 106 shares during the last quarter. PDS Planning Inc raised its stake in Boston Scientific by 1.5% during the 4th quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock valued at $668,000 after buying an additional 113 shares during the last quarter. Adero Partners LLC boosted its stake in shares of Boston Scientific by 3.3% in the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after buying an additional 120 shares during the last quarter. Finally, Tradition Wealth Management LLC grew its holdings in shares of Boston Scientific by 2.2% in the fourth quarter. Tradition Wealth Management LLC now owns 5,510 shares of the medical equipment provider's stock worth $492,000 after acquiring an additional 121 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.82 on Friday, reaching $101.96. The company's stock had a trading volume of 5,412,952 shares, compared to its average volume of 6,374,152. The stock's fifty day simple moving average is $98.75 and its 200-day simple moving average is $94.69. Boston Scientific Co. has a 1 year low of $70.97 and a 1 year high of $107.17. The company has a market capitalization of $150.81 billion, a price-to-earnings ratio of 81.57, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. This trade represents a 11.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock worth $14,407,381 over the last ninety days. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on BSX shares. Evercore ISI boosted their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday. Morgan Stanley lifted their target price on Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Barclays raised their price objective on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday. Citigroup increased their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Finally, Robert W. Baird lifted their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday. One investment analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.